

Valeant Pharmaceuticals International, Inc.  
Form 15-12B  
October 27, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)  
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS  
UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission File Number 001-11397**

**VALEANT PHARMACEUTICALS INTERNATIONAL**

(Exact name of registrant as specified in its charter)

**One Enterprise  
Aliso Viejo, California 92656  
(949) 461-6000**

(Address, including zip code, and telephone number, including area code, of  
registrant's principal executive offices)

**8.375% Senior Notes due 2016**

(Title of each class of securities covered by this Form)

**None**

(Titles of all other classes of securities for which a duty to file reports  
under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend  
the duty to file reports:

Rule 12g-4(a)(1)	<input type="radio"/>
Rule 12g-4(a)(2)	<input type="radio"/>
Rule 12h-3(b)(1)(i)	<input checked="" type="radio"/>
Rule 12h-3(b)(1)(ii)	<input type="radio"/>
Rule 15d-6	<input type="radio"/>

Approximate number of holders of record as of the certification or notice date: none

Pursuant to the requirements of the Securities Exchange Act of 1934, Valeant Pharmaceuticals International has  
caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

October 27, 2010

By: /s/ Robert Chai-Onn  
Robert Chai-Onn  
Executive Vice President, General  
Counsel  
and Corporate Secretary